Uveitis refers to inflammation of the middle layer of the eye known as the uvea that includes the iris, choroid, and ciliary body.
Uveitis refers to a group of conditions that cause inflammation of the pigmented middle layer of the eye known as the uvea. There are different types of uveitis depending on the area of the uvea affected which may be unilateral or bilateral. Anterior uveitis is the most common form, which classically causes a painful red eye, whereas posterior uveitis more typically causes visual changes, floaters, and flashing lights.
Patients with suspected uveitis should be referred to an ophthalmologist urgently for assessment within 24 hours. The diagnosis is usually clinical based on slit-lamp examination and patients will need to be assessed for an underlying systemic autoimmune disease which is present in up to 40% of cases.
The uvea, or uveal tract, refers to the vascular middle layer of the eye that lies between the sclera and retina.
The uvea is the pigmented middle layer of the eye. It is essential for controlling the amount of light entering the eye, the shape of the lens for accommodation, and providing nourishment to the retina which includes photoreceptor cells.
The uvea is divided into three components:
Uveitis is divided into different types depending on the location that is affected.
Uveitis is broadly classified by the area of the uvea that is affected. The anterior portion of the uvea includes the iris and ciliary body. The posterior portion of the uvea is known as the choroid.
The terminology (i.e. descriptors) use to describe uveitis and its subsequent classification is based on the Standardization of Uveitis Nomenclature (SUN). This divides uveitis into anterior, intermediate, posterior, and panuveitis depending on the anatomical structures that are involved. Descriptive terms may then be used to describe uveitis including onset (sudden, insidious), duration (limited, persistent), and course (acute, chronic, recurrent).
Uveitis may be anterior, posterior, or panuveitis. The term intermediate uveitis may be used separately but here we group it with posterior uveitis:
Uveitis may be further divided based on the onset, duration, and course of the illness.
Uveitis may be acute, chronic, or recurrent:
Anterior uveitis is the most common form seen in > 90% of cases in the Western world.
Uveitis can occur at any age but is more common in patients 20-50 years old. The annual incidence of uveitis is estimated at 12 per 100,000 population. However, differences in incidence, prevalence, and gender distribution depend on the underlying cause. Worldwide, uveitis is a major cause of visual impairment, particularly in the developing world.
There are various causes of uveitis, but up to 30% of cases may be idiopathic (i.e. no known cause).
Uveitis may be caused by a range of different pathologies. These are broadly divided into three main categories:
A variety of different infectious organisms may lead to uveitis. The clinical presentation is often typical of the underlying pathogen, but the development of infective uveitis depends on multiple factors including host immunity and geography.
Typical infective causes include:
An underlying systemic inflammatory disorder is identified in around 40% of patients with uveitis. Classically, anterior uveitis is associated with a group of conditions known as spondyloarthropathies, which includes Ankylosing Spondylitis. Anterior uveitis is seen in 20-40% of patients with these conditions, which is associated with the human leucocyte antigen HLA B27 (see pathophysiology).
Many inflammatory disorders are associated with uveitis including:
This refers to conditions that cause uveitis usually in the absence of systemic features. Systemic features are typical of an infective or inflammatory syndrome. Examples include:
Several conditions may give rise to the suspicion of uveitis due to the presence of leucocytes in the anterior chamber (a hallmark of anterior uveitis). The presence of cells in the absence of inflammation is typical of an underlying haematological process (e.g. lymphoma, leukaemia).
Anterior uveitis is characterised by inflammation in the anterior chamber that can lead to the formation of a hypopyon.
The exact mechanisms leading to uveitis are not well understood and depend on the underlying aetiology. In infective causes, there may be direct intra-ocular damage or secondary effects due to the release of exo- or endotoxins that result in the recruitment and infiltration of immune cells leading to ocular damage. In inflammatory causes, there is thought to be an abnormal response to ocular antigens leading to an autoimmune response that promotes tissue damage.
The infiltration of immune cells that promote and propagate the inflammatory response causes the characteristic finding of 'cells and flares'. This refers to leucocytes floating within the aqueous humour of the anterior chamber (cells) and a foggy appearance due to an increase in protein concentration (flare). In significant inflammation, these cells may precipitate to form a fluid level known as a hypopyon.
Patients with the human leucocyte antigen HLA-B27 are at an increased risk of developing anterior uveitis. HLA-B27 is a type of major histocompatibility complex (MHC) molecule that is involved in the regulation of the adaptive immune response through the presentation of intracellular peptides to immune cells. HLA-B27 is a specific allele that is particularly common in Caucasians (5-6% prevalence). Approximately 50% of all patients with anterior uveitis have the HLA-B27 allele, although the risk of anterior uveitis in patients with HLA-B27 is only 1% across a lifetime. This means that other factors are implicated in its development.
Anterior uveitis is characterised by a painful, red eye that is predominantly located around the limbus.
The symptoms of uveitis depend on the underlying cause and the area of the uvea that is affected. Infectious and inflammatory causes are likely to present with additional systemic features (e.g. joint pain, fever, rash). Anterior uveitis is characterised by pain and redness, whereas posterior uveitis presents with more non-specific visual symptoms such as floaters and visual disturbance.
Uveitis may be unilateral or bilateral. For example, anterior uveitis associated with spondyloarthropathy is commonly unilateral, whereas uveitis associated with inflammatory bowel disease is frequently bilateral.
Patients with suspected uveitis should be referred for urgent ophthalmic assessment within 24 hours.
The diagnosis of uveitis is usually clinical based on the history, examination, and slit-lamp findings. There are many serious causes of a painful red eye with or without reduced vision. Therefore, patients were red flag signs (e.g. photophobia, visual impairment, severe eye pain, or persistent redness) should be referred for urgent ophthalmic assessment, ideally same-day, but otherwise within 24 hours.
A formal diagnosis of uveitis requires a slit-lamp examination. This is a non-invasive examination of the eye to assess the eye structures in more detail. It uses a biomicroscope, which emits a thin, intense beam of light to illuminate the anterior segment of the eye that includes the cornea, iris, and lens. Slit lamp indirect ophthalmoscopy may then be used to examine the posterior segment of the eye after pupil dilatation.
Features that support the diagnosis of uveitis on slit-lamp examination include:
Given the association of uveitis with an underlying infective or inflammatory disorder, it is important to undertake a full work-up for a systemic cause. Diagnostic testing, for example, bloods, imaging, and HLA-B27, should be guided by the history and examination findings. Typical investigations that can be done include:
The predominant treatment of non-infectious anterior uveitis is with topical glucocorticoids.
Uveitis should be managed by an ophthalmologist. In non-infectious causes, the principal treatment of anterior uveitis is with steroids (e.g. Topical prednisolone acetate). However, these can be very dangerous in the context of an alternative diagnosis or infection. Posterior uveitis is usually not responsive to topical agents and may require an intra-ocular corticosteroid injection.
The treatment of infective uveitis should be directed toward the underlying cause. For example, anti-viral therapy should be used for patients with suspected herpes-simplex-associated uveitis.
The principal treatment of non-infective uveitis is corticosteroids. In anterior uveitis, which is more common, the choice is usually topical corticosteroids, whereas posterior uveitis may require an intra-ocular steroid injection. Steroids are generally tapered slowly to avoid rebound inflammation. It is important to recognise that steroids, including topical steroids, can be associated with significant ophthalmic side-effects including raised intra-ocular pressure and cataracts
Patients with resistant or bilateral disease may require early systemic therapy including oral corticosteroids and/or immunosuppressive agents (e.g. methotrexate or anti-tumour necrosis factor alpha therapy).
Topical agents to paralyse the ciliary body may be used to help relieve pain and prevent the formation of adhesions (i.e. posterior synechiae). These drugs such as cyclopentolate 1% or atropine 1% are anti-muscarinic agents that dilate the eye (known as mydriatics).
Chronic uveitis is a major cause of visual impairment.
Good long-term outcomes in patients with uveitis usually depend on the underlying cause, severity and location of inflammation, and degree of visual impairment. Factors such as poor visual acuity at presentation, bilateral involvement, and/or the presence of juvenile idiopathic arthritis are all associated with a worse outcome. Acute anterior uveitis is generally considered to have the best outcome, and chronic, non-infectious, posterior uveitis a much worst outcome.
The main complications associated with uveitis include:
Have comments about these notes? Leave us feedback